<DOC>
	<DOCNO>NCT00478608</DOCNO>
	<brief_summary>Primary : To evaluate efficacy sirolimus assess incidence biopsy-confirmed acute rejection episode 6 month transplantation Korean renal transplantation recipient . Secondary : 1 . To evaluate safety sirolimus 12 month transplantation Korean renal transplantation recipient . 2 . To evaluate graft function , patient survival graft survival 6 12 month transplantation , investigate incidence biopsy-confirmed acute rejection episode 12 month transplantation .</brief_summary>
	<brief_title>Study Evaluating RapamuneÂ® Maintenance Regimen</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age great equal 13 year age . 2 . Endstage renal disease patient schedule receive primary renal allograft cadaveric donor , livingunrelated donor , livingrelated ( exclude 0 antigen mismatch ) donor . A mismatch donor define donor human leukocyte antigen ( HLA ) antigen share patient . 3 . Patients panel reactive antibody ( % PRA ) less equal 50 % 1 . Evidence active systemic localize major infection time initial sirolimus administration . 2 . Evidence infiltrate , cavitation , consolidation chest xray obtain prestudy screening . 3 . Chronic antiarrhythmic therapy ventricular arrhythmia cardiac abnormality contraindicate general anesthesia surgery . 4 . History malignancy within 5 year enrollment study ( exception adequately treat basal cell squamous cell carcinoma skin ) . 5 . Current treatment partial opioid agonist ( eg , buprenorphine ) combination agonists/antagonists .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>